Nutriband Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nutriband Inc. (Nasdaq: NTRB) on February 13, 2026. The report addresses a material event regarding the termination of a subsidiary sale agreement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial figure disclosed is $30,000 in late fees received from the purchaser prior to the termination of the agreement.
Material Changes
- Termination of Sale Agreement: The Board of Directors approved the immediate termination of the agreement to sell the subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision BioInc.
- Reason for Termination: The purchaser failed to pay applicable late fees under the purchase agreement and did not close on the scheduled December 31, 2025, closing date.
- Payment Status: The Company received $30,000 in late fees but has not received any further payments since January 21, 2026.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate failure of the transaction. The primary contingency noted is the loss of the potential sale of Pocono Pharmaceuticals, Inc.
Investor Verification Checklist
- Verify the current status of Pocono Pharmaceuticals, Inc. and whether a new sale process is being initiated.
- Confirm the total amount of late fees received ($30,000) and whether any legal action is being pursued for the remaining unpaid fees.
- Review the original purchase agreement terms to understand the specific late fee obligations that were breached.
- Check for any subsequent filings regarding the financial impact of this termination on the Company's liquidity.